Get started

Financials · JAZZ

Jazz Pharmaceuticals plc (JAZZ) financials

For the twelve months ended Sep 30, 2026, Jazz Pharmaceuticals plc reported $4.72B of revenue and $205.95M of net income.

Revenue, TTM
$4.72B
Revenue growth, YoY
+13.5%
Net income, TTM
$205.95M
Net margin
4.4%
Free cash flow, TTM
$1.62B
EPS, diluted, TTM
$3.07
Cash
$2.04B
Total debt
$5.57B
P/E
75.28
P/S
3.29
Market cap
$15.50B
Annual revenue$4.27B
FY2016FY2025
Annual net income-$356.15M
FY2016FY2025
Annual free cash flow$1.30B
FY2016FY2025

JAZZ revenue and earnings growth

JAZZ revenueQ3 2026$1.24B

Quarter YoY
+10.4%
QoQ
+2.9%
FY YoY
+4.9%
5Y CAGR
+12.5%
10Y CAGR
+12.4%

JAZZ revenue was $1.24B in fiscal Q3 2026 (ended Sep 30, 2026), up 10.4% from a year earlier and up 2.9% from the prior quarter. For the full fiscal 2025 it was $4.27B, up 4.9% from fiscal 2024. Compound annual growth was +12.5% over 5 years and +12.4% over 10 years. It rose in each of the last 10 fiscal years. Fiscal 2025 is the highest of the 15 fiscal years on file.

JAZZ net incomeQ3 2026-$483.40M

JAZZ net income was -$483.40M in fiscal Q3 2026 (ended Sep 30, 2026), compared with $251.40M a year earlier. For the full fiscal 2025 it was -$356.15M, compared with $560.12M in fiscal 2024.

JAZZ EPSQ3 2026-$7.48

JAZZ diluted EPS was -$7.48 in fiscal Q3 2026 (ended Sep 30, 2026), compared with $4.08 a year earlier. For the full fiscal 2025 it was -$5.84, compared with $8.65 in fiscal 2024.

JAZZ free cash flowQ3 2026$489.90M

Quarter YoY
+6.6%
QoQ
+23.2%
FY YoY
-4.5%
5Y CAGR
+8.0%
10Y CAGR
+10.1%

JAZZ free cash flow was $489.90M in fiscal Q3 2026 (ended Sep 30, 2026), up 6.6% from a year earlier and up 23.2% from the prior quarter. For the full fiscal 2025 it was $1.30B, down 4.5% from fiscal 2024. Compound annual growth was +8.0% over 5 years and +10.1% over 10 years. It rose in 6 of the last 10 fiscal years.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue$4.27B$4.07B$3.83B$3.66B$3.09B$2.36B$2.16B$1.89B$1.62B$1.49B
Research and development$782.74M$884.00M$849.66M$590.45M$505.75M$335.38M$299.73M$226.62M$198.44M$162.30M
Selling, general and admin$1.81B$1.39B$1.34B$1.42B$1.45B$854.23M$736.94M$683.53M$544.16M$502.89M
Operating income-$430.24M$716.63M$578.58M-$65.53M$170.28M$378.07M$532.37M$614.84M$528.84M$591.65M
Pre-tax income-$627.86M$470.35M$297.93M-$372.78M-$112.84M$275.10M$454.30M$529.46M$441.12M$532.45M
Income tax-$272.44M-$91.43M-$119.91M-$158.65M$216.12M$33.52M-$73.15M$80.16M-$47.74M$135.24M
Net income-$356.15M$560.12M$414.83M-$224.06M-$329.67M$238.62M$523.37M$447.10M$487.85M$396.83M
EPS, basic-$5.84$9.06$6.55-$3.58-$5.52$4.28$9.22$7.45$8.13$6.56
EPS, diluted-$5.84$8.65$6.10-$3.58-$5.52$4.22$9.09$7.30$7.96$6.41
Diluted shares61.0M66.0M72.1M62.5M59.7M56.5M57.5M61.2M61.3M61.9M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$1.39B$2.41B$1.51B$881.48M$591.45M$1.06B$637.34M$309.62M$386.04M$365.96M
Receivables$830.70M$716.76M$705.79M$651.49M$563.36M$396.49M$355.99M$263.84M$224.13M$234.24M
Inventory$417.00M$480.44M$597.04M$714.06M$1.07B$95.40M$78.61M$52.96M$43.24M$34.05M
Current assets$4.17B$4.63B$3.44B$2.61B$2.61B$2.84B$1.63B$1.23B$968.28M$748.07M
Goodwill$1.83B$1.72B$1.75B$1.69B$1.83B$958.30M$920.02M$927.63M$947.54M$893.81M
Total assets$11.66B$12.01B$11.39B$10.84B$12.30B$6.54B$5.54B$5.20B$5.12B$4.80B
Current liabilities$2.24B$1.04B$1.54B$933.19M$809.30M$653.75M$364.49M$345.49M$293.95M$257.41M
Short-term debt$1.03B$31.00M$604.95M$31.00M$31.00M$246.32M$33.39M$33.39M$40.60M$36.09M
Long-term debt$4.33B$6.08B$5.11B$5.69B$6.02B$1.85B$1.57B$1.56B$1.54B$1.99B
Total debt$5.36B$6.11B$5.71B$5.72B$6.05B$2.09B$1.61B$1.60B$1.58B$2.03B
Total liabilities-------$2.45B$2.41B$2.92B
Shareholders' equity$4.32B$4.09B$3.74B$3.09B$3.97B$3.66B$3.11B$2.76B$2.71B$1.88B

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow$1.36B$1.40B$1.09B$1.27B$778.51M$899.65M$776.40M$798.90M$693.09M$592.39M
Capital expenditures$58.75M$38.07M$23.96M$29.05M$27.64M$15.00M$40.13M$20.37M$28.95M$9.69M
Free cash flow$1.30B$1.36B$1.07B$1.24B$750.87M$884.64M$736.27M$778.53M$664.14M$582.70M
Investing cash flow-$1.51B-$508.19M-$163.06M-$446.23M-$5.21B-$1.01B-$155.30M-$394.49M-$268.95M-$1.75B
Financing cash flow-$873.38M$20.52M-$305.25M-$529.49M$3.97B$528.07M-$293.75M-$479.13M-$409.11M$540.99M
Share repurchases$125.02M$311.43M$269.76M$54.0K$0$146.54M$301.45M$523.67M$98.80M$278.30M
Stock-based compensation$291.13M$248.04M$226.84M$222.00M$189.01M$121.00M$110.56M$102.44M$106.90M$98.77M
Depreciation and amortization$41.60M$32.80M$30.40M$30.30M$26.70M$18.70M$15.30M$15.20M$13.10M$11.80M

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY4.9%6.1%4.8%18.3%30.9%9.3%14.3%16.8%8.8%12.3%
Net income growth, YoY-35.0%----54.4%17.1%-8.4%22.9%20.4%
EPS growth, YoY-41.8%----53.6%24.5%-8.3%24.2%22.6%
Operating margin-10.1%17.6%15.1%-1.8%5.5%16.0%24.6%32.5%32.7%39.8%
Net margin-8.3%13.8%10.8%-6.1%-10.7%10.1%24.2%23.6%30.1%26.7%
Free cash flow margin30.4%33.4%27.9%34.0%24.3%37.4%34.1%41.2%41.0%39.2%
Return on equity-8.2%13.7%11.1%-7.3%-8.3%6.5%16.8%16.2%18.0%21.1%
Return on assets-3.1%4.7%3.6%-2.1%-2.7%3.7%9.4%8.6%9.5%8.3%
Current ratio1.864.462.242.793.234.344.473.573.292.91
Debt to equity1.241.491.531.861.530.570.520.580.581.08

Source: XBRL data Jazz Pharmaceuticals plc files with the SEC, latest filing dated Nov 2, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

JAZZ peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
JAZZ$4.72B+13.5%$205.95M4.4%$15.50B
LLY$86.46B+45.5%$27.58B31.9%$1.36T
JNJ$99.33B+7.8%$16.09B16.2%$687.89B
ABBV$66.01B+10.7%$10.34B15.7%$521.50B
MRK$67.38B+4.9%$2.45B3.6%$364.26B
NVS$54.53B+8.4%$13.98B25.6%$306.26B
AZN$58.74B+8.6%$10.22B17.4%$286.03B
ABT$48.23B+10.0%$4.70B9.7%$187.95B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$184.33B

JAZZ FAQ

8 questions
  • What is JAZZ revenue?
    Jazz Pharmaceuticals plc (JAZZ) reported $4.72B of revenue for the twelve months ended Sep 30, 2026. That is up 13.5% from the year before. Revenue for fiscal 2025 was $4.27B.
  • Is JAZZ profitable?
    Yes. Jazz Pharmaceuticals plc earned $205.95M in net income for the twelve months ended Sep 30, 2026, a net margin of 4.4%.
  • How much cash and debt does JAZZ have?
    Jazz Pharmaceuticals plc reported $2.04B in cash and cash equivalents and $5.57B of debt on its most recent balance sheet in SEC filings.
  • How fast is JAZZ revenue growing?
    Jazz Pharmaceuticals plc's revenue changed +4.9% in fiscal 2025, to $4.27B. Its compound annual growth rate was +12.5% over 5 years and +12.4% over 10 years.
  • What is JAZZ free cash flow?
    Jazz Pharmaceuticals plc generated $1.62B of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of $1.69B less capital expenditures.
  • What is JAZZ earnings per share?
    Diluted earnings per share were $3.07 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did JAZZ last report financial results?
    The latest statements here come from Jazz Pharmaceuticals plc's 10-Q filed on Nov 2, 2026, covering the period ended Sep 30, 2026.
  • Where does this JAZZ financial data come from?
    Quantisnow builds these statements from the structured XBRL data Jazz Pharmaceuticals plc files with the SEC. It is provided for information only and is not investment advice.